Owens & Minor executive vice president and CIO Snehashish Sarkar to resign

Owens & Minor (NYSE:OMI) reported mixed Q2 2025 earnings, with EPS of $0.26 missing forecasts by 10.34% despite a 3.3% year-over-year revenue increase to $682 million. Concurrently, EVP and CIO Snehashish Sarkar announced his resignation effective September 2025. UBS responded by lowering OMI's price target to $7.00 from $13.00, citing concerns over dis-synergies from the Patient & Healthcare Services sale and the loss of Kaiser impacting 2026 EBIT, while maintaining a 'Buy' rating due to potential debt reduction from the estimated $700 million P&HS sale proceeds.

Analysis

Owens & Minor (OMI) presents a mixed financial profile marked by conflicting operational results and forward-looking risks. The company's second-quarter 2025 revenue grew 3.3% year-over-year to $682 million, indicating some top-line resilience. However, this was overshadowed by an earnings per share of $0.26, which missed analyst forecasts by 10.34%. This underperformance is compounded by significant strategic and leadership uncertainty. An impending executive departure, with CIO Snehashish Sarkar set to resign in September 2025, introduces potential disruption in a key functional area. Furthermore, analyst firm UBS has drastically cut its price target to $7.00 from $13.00, citing near-term 'dis-synergies' from the sale of its Patient & Healthcare Services (P&HS) division and the negative impact on 2026 EBIT from losing the Kaiser contract. Despite these headwinds, UBS maintains a 'Buy' rating, predicated on the potential for the estimated $700 million in proceeds from the P&HS sale to substantially reduce corporate debt.

Key Decisions for Investors

• Investors should weigh the potential for balance sheet improvement via debt reduction from the $700 million P&HS sale against the significant execution risks highlighted by the earnings miss and upcoming CIO transition.
• Monitor management's commentary on mitigating the 'dis-synergies' from the P&HS sale and the earnings impact from the Kaiser contract loss, as these are the key drivers behind UBS's severe price target reduction.
• Given the conflicting signals of a 'Buy' rating and a 46% price target cut, a cautious stance is warranted until there is greater clarity on post-restructuring margins and a stable leadership team is confirmed.